+ 49 (0) 2204 2918806

XenoPort, Inc. – Product Pipeline Review – 2013

SKU:GMDHC03640CDB / 329942
Publication Date:30.04.2013
Language version:English
Report Type:Report
Lieferzeit:2-3 Tage
Nr of pages:66 pages
Rating:Für diese Studie liegt keine Bewertung vor.
$1,500.00   *
* Click here to switch the currency you want to pay in.
More about this report
Table of Contents
Other relevant reports
Our guarantee

Content of the report


Global Market Direct’s pharmaceuticals report, “XenoPort, Inc. - Product Pipeline Review - 2013” provides data on the XenoPort, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, XenoPort, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from XenoPort, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


- XenoPort, Inc. - Brief XenoPort, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of XenoPort, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of XenoPort, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the XenoPort, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy

- Evaluate XenoPort, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of XenoPort, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the XenoPort, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with XenoPort, Inc
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of XenoPort, Inc. and identify potential opportunities in those areas.